Medpage Today on MSN4d
Higher Comorbidity Burden in Multiple Sclerosis Tied to Worse Outcomes
"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...
Rutgers University6d
Testing a Revolutionary Treatment Against Progressive Multiple Sclerosis
Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an ...
BioTechniques2d
Biomarkers for predicting multiple sclerosis progression identified
Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...
STAT9d
FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug
Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
DAYBREAK was a Phase 3, multi-center, long-term open-label extension study to evaluate the safety and efficacy of Zeposia (ozanimod) administered orally to patients with relapsing forms of multiple ...
Investing9d
FDA approves new multiple sclerosis treatment OCREVUS ZUNOVO
This approval introduces a subcutaneous (SC) injection option for patients with relapsing multiple sclerosis ... in the treatment of MS, particularly benefiting centers without IV infrastructure ...
Cardarelli Hospital Inaugurates New Department for Multiple Sclerosis Patients
Today is an important day for Cardarelli as it inaugurates a department dedicated to patients with multiple sclerosis. We ...